secwatch.observer — SEC 8-K summary
======================================

Issuer:     NKGen Biotech, Inc. (—)
CIK:        0001845459
Form:       8-K
Filed at:   2025-09-09T23:59:59+00:00
Accession:  0001213900-25-085858
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NKGen completes acquisition of 65% stake in NKMax for ~$17M, gaining full control of manufacturing and IP
--------------------------------------------------------------------------------

- Acquired 46.4M shares at ~$0.36/share, representing 65% interest in NKMax out of bankruptcy.
- Funding of ~$17M: majority from AlpineBrook Capital GP I Limited, remainder from CEO Paul Y. Song; terms pending.
- Transaction grants NKGen full control of NKMax's global manufacturing infrastructure, IP, and exclusive commercialization rights.
- NKGen expects to accelerate clinical development of troculeucel (Alzheimer's therapy) and expand NK cell therapy pipeline.
- NKGen stock trades on OTC Expert Market; removal of parent overhang may renew investor interest.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1845459/000121390025085858/0001213900-25-085858-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1845459/000121390025085858/ea0256553-8k_nkgen.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-085858

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer